Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 14/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | GCK | P35557 | 1/20 | 0.31 |
| ▸ | GCKR | Q14397 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25031243 | 0.86 | KIF11 (0.40) | HSD11B1ALDH1A1 | |
| SCHEMBL25031393 | 0.83 | ALDH1A1 (0.42) | ALDH1A1 | |
| SCHEMBL25031378 | 0.83 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL20692191 | 0.83 | SMYD3 (0.32) | HSD11B1ALDH1A1 | |
| SCHEMBL25030620 | 0.83 | CA2 (0.43) | HSD11B1ALDH1A1 | |
| SCHEMBL24773026 | 0.81 | ALDH1A1 (0.47) | HSD11B1ALDH1A1HTR6 | |
| SCHEMBL20681591 | 0.81 | HSD11B1 (0.42) | HSD11B1ALDH1A1NR1I2GCKGCKR | |
| SCHEMBL22012107 | 0.79 | CYP11B2 (0.32) | HSD11B1 | |
| SCHEMBL25031248 | 0.77 | TP53 (0.36) | HSD11B1ALDH1A1 | |
| SCHEMBL24978777 | 0.76 | HSD11B1 (0.30) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | HSD11B1 324/4885ALDH1A1 1972/4885NR1I2 1276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.